Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by RenovoRx, Inc.

< Previous 1 2 Next >
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Reports Third Quarter 2022 Financial Results
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Participate in Upcoming October 2022 Investor Conferences
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Reports Second Quarter 2022 Financial Results
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Appoints James Ahlers as Chief Financial Officer
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Launches “The RenovoRx Story” Video Series
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx and TIGeR-PaC Leadership to Host RenovoTAMP™ Webinar on June 21, 2022
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Participate in the University of Cambridge’s Academy of Therapeutic Sciences Gateway to Translation Seminar Series on June 8, 2022
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platform’s Potential Utility for the Treatment of Bile Duct Cancer
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx to Participate in Upcoming H.C Wainwright Global Investment Conference in May 2022
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Reports First Quarter 2022 Financial Results
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride Event to End Pancreatic Cancer
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports Full Year 2021 Financial Results
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial
From RenovoRx, Inc.
Via Business Wire
Tickers RNXT
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.